bioAffinity and AvMEDICAL bring CyPath Lung test to VA conference
The companies presented their new federal distribution partnership for the noninvasive lung cancer test to VA leaders and physicians in Arlington, Virginia.
SEC filing
Latest
5 stories
Yesterday
Thursday, September 3
bioAffinity Technologies to present at H.C. Wainwright investment conference
The company disclosed in a September 3, 2026 filing that CEO Maria Zannes will meet with investors during the September 14-16 conference, alongside details on its share count and market value.
SEC filing
Friday, August 14
bioAffinity Technologies closes $4 million private placement of pre-funded warrants
The San Antonio diagnostics company sold pre-funded warrants and companion warrants to an institutional investor, closing the deal on August 14, 2026.
SEC filing
Friday, August 7
bioAffinity reports Q2 2026 CyPath Lung test volume up 216% year over year
The company said its longitudinal clinical trial has begun enrolling patients at 11 sites while cash fell to $2.4 million as of June 30, 2026.
SEC filing
Wednesday, July 22
bioAffinity Technologies partners with Pictor on asthma and COPD diagnostics
The San Antonio biotech will combine its flow cytometry work with Pictor's proteomic platform to build tests aimed at guiding personalized asthma and COPD treatment.
SEC filing